Literature DB >> 34632629

Autopsy Validation of Progressive Supranuclear Palsy-Predominant Speech/Language Disorder Criteria.

Fatma Ozlem Hokelekli1, Joseph R Duffy1, Heather M Clark1, Rene L Utianski1, Hugo Botha1, Farwa Ali1, Julie A Stierwalt1, Mary M Machulda2, R Ross Reichard3, Dennis W Dickson4, Jennifer L Whitwell5, Keith A Josephs1.   

Abstract

BACKGROUND: Progressive supranuclear palsy (PSP) may present as a speech/language disorder (PSP-SL).
OBJECTIVE: We assessed pathological correlates of patients with PSP-SL who retained the suggestive of PSP-SL (s.o. PSP-SL) diagnosis versus those who progressed to possible/probable (poss./prob.) PSP.
METHODS: Thirty-four prospectively recruited patient with s.o. PSP-SL completed comprehensive speech/language and neurological assessments longitudinally, died, and underwent autopsy.
RESULTS: Twelve patients (35%) evolved to poss./prob PSP, while 22 (65%) remained as s.o. PSP-SL. Pathological diagnoses differed across the groups (P = 0.025). Patients with s.o. PSP-SL had four different neuropathologies (corticobasal degeneration [59%], PSP [13%], Pick's disease [14%], and frontotemporal lobar degeneration with TDP-43 [14%]), while all patients with poss./prob. PSP had a 4R-tauopathy (PSP [67%] and corticobasal degeneration [33%]). Development of poss./prob. PSP increased the chance of having PSP pathology by 2.38 times.
CONCLUSIONS: PSP-SL is associated with heterogenous pathologies. Evolution of PSP-SL into poss./prob. PSP is more predictive of underlying PSP pathology than s.o. PSP-SL.
© 2021 International Parkinson and Movement Disorder Society. © 2021 International Parkinson and Movement Disorder Society.

Entities:  

Keywords:  PSP; criteria; language; pathology; speech

Mesh:

Year:  2021        PMID: 34632629      PMCID: PMC8770531          DOI: 10.1002/mds.28822

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  30 in total

1.  The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment.

Authors:  Ziad S Nasreddine; Natalie A Phillips; Valérie Bédirian; Simon Charbonneau; Victor Whitehead; Isabelle Collin; Jeffrey L Cummings; Howard Chertkow
Journal:  J Am Geriatr Soc       Date:  2005-04       Impact factor: 5.562

2.  Sensitivity and Specificity of Diagnostic Criteria for Progressive Supranuclear Palsy.

Authors:  Farwa Ali; Peter R Martin; Hugo Botha; J Eric Ahlskog; James H Bower; Joseph Y Masumoto; Demetrius Maraganore; Anhar Hassan; Scott Eggers; Bradley F Boeve; David S Knopman; Daniel Drubach; Ronald C Petersen; Erika Driver Dunkley; Jay van Gerpen; Ryan Uitti; Jennifer L Whitwell; Dennis W Dickson; Keith A Josephs
Journal:  Mov Disord       Date:  2019-02-06       Impact factor: 10.338

3.  Natural history and survival of 14 patients with corticobasal degeneration confirmed at postmortem examination.

Authors:  G K Wenning; I Litvan; J Jankovic; R Granata; C A Mangone; A McKee; W Poewe; K Jellinger; K Ray Chaudhuri; L D'Olhaberriague; R K Pearce
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-02       Impact factor: 10.154

4.  The FAB: a Frontal Assessment Battery at bedside.

Authors:  B Dubois; A Slachevsky; I Litvan; B Pillon
Journal:  Neurology       Date:  2000-12-12       Impact factor: 9.910

5.  Neuroanatomical correlates of the progressive supranuclear palsy corticobasal syndrome hybrid.

Authors:  K A Josephs; S D Z Eggers; C R Jack; J L Whitwell
Journal:  Eur J Neurol       Date:  2012-04-23       Impact factor: 6.089

6.  Clinicopathological and imaging correlates of progressive aphasia and apraxia of speech.

Authors:  Keith A Josephs; Joseph R Duffy; Edyth A Strand; Jennifer L Whitwell; Kenneth F Layton; Joseph E Parisi; Mary F Hauser; Robert J Witte; Bradley F Boeve; David S Knopman; Dennis W Dickson; Clifford R Jack; Ronald C Petersen
Journal:  Brain       Date:  2006-04-13       Impact factor: 13.501

Review 7.  Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy).

Authors:  J J Hauw; S E Daniel; D Dickson; D S Horoupian; K Jellinger; P L Lantos; A McKee; M Tabaton; I Litvan
Journal:  Neurology       Date:  1994-11       Impact factor: 9.910

8.  Sensitivity-Specificity of Tau and Amyloid β Positron Emission Tomography in Frontotemporal Lobar Degeneration.

Authors:  Alma Ghirelli; Nirubol Tosakulwong; Stephen D Weigand; Heather M Clark; Farwa Ali; Hugo Botha; Joseph R Duffy; Rene L Utianski; Marina Buciuc; Melissa E Murray; Sydney A Labuzan; Anthony J Spychalla; Nha Trang Thu Pham; Christopher G Schwarz; Matthew L Senjem; Mary M Machulda; Matthew Baker; Rosa Rademakers; Massimo Filippi; Clifford R Jack; Val J Lowe; Joseph E Parisi; Dennis W Dickson; Keith A Josephs; Jennifer L Whitwell
Journal:  Ann Neurol       Date:  2020-09-12       Impact factor: 10.422

9.  Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan.

Authors:  Christopher G Goetz; Stanley Fahn; Pablo Martinez-Martin; Werner Poewe; Cristina Sampaio; Glenn T Stebbins; Matthew B Stern; Barbara C Tilley; Richard Dodel; Bruno Dubois; Robert Holloway; Joseph Jankovic; Jaime Kulisevsky; Anthony E Lang; Andrew Lees; Sue Leurgans; Peter A LeWitt; David Nyenhuis; C Warren Olanow; Olivier Rascol; Anette Schrag; Jeanne A Teresi; Jacobus J Van Hilten; Nancy LaPelle
Journal:  Mov Disord       Date:  2007-01       Impact factor: 10.338

10.  Clinical Conditions "Suggestive of Progressive Supranuclear Palsy"-Diagnostic Performance.

Authors:  Max-Joseph Grimm; Gesine Respondek; Maria Stamelou; Thomas Arzberger; Leslie Ferguson; Ellen Gelpi; Armin Giese; Murray Grossman; David J Irwin; Alexander Pantelyat; Alex Rajput; Sigrun Roeber; John C van Swieten; Claire Troakes; Wassilios G Meissner; Christer Nilsson; Ines Piot; Yaroslau Compta; James B Rowe; Günter U Höglinger
Journal:  Mov Disord       Date:  2020-09-11       Impact factor: 10.338

View more
  2 in total

1.  Brainstem Biomarkers of Clinical Variant and Pathology in Progressive Supranuclear Palsy.

Authors:  Rosalie M Grijalva; Nha Trang Thu Pham; Qiao Huang; Peter R Martin; Farwa Ali; Heather M Clark; Joseph R Duffy; Rene L Utianski; Hugo Botha; Mary M Machulda; Stephen D Weigand; J Eric Ahlskog; Dennis W Dickson; Keith A Josephs; Jennifer L Whitwell
Journal:  Mov Disord       Date:  2021-12-31       Impact factor: 9.698

Review 2.  Clinical Spectrum of Tauopathies.

Authors:  Nahid Olfati; Ali Shoeibi; Irene Litvan
Journal:  Front Neurol       Date:  2022-07-14       Impact factor: 4.086

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.